Preliminary results suggested that EGFR wild-type lung cancer cell H1650 and EGFR mutant lung cancer H1975 cells showed poor sensitivity to icotinib with IC50 values of >50 μM, and icotinib-triazole derivatives such as 3b, 3d, 3e, 3g, 3i, 3k, 3l, 3n, 3o and 3v all exhibited stronger killing effects on the above lung cancer cell lines than icotinib did. This evidence concerns the gene EGFR and lung carcinoma.